The biotech will relinquish its rights to the mid-stage WX-554 and WX-037 and give back three preclinical antibody therapies, terminating a separate, non-oncology development deal with UCB in the process, Wilex said. The company will get a final undisclosed R&D payment from its soon-to-be-ex-collaborator, and UCB has agreed to waive repayment a €2.5 million ($3.4 million) term loan, sparing the cash-strapped Wilex from further loss.
The hand-off is part of a strategic alignment that saw Wilex cut 80% of its staff in January, kicking off a tiered exit from all clinical activity. The plan is sell off or out-license all of its proprietary assets and focus on its revenue-generating Heidelberg Pharma subsidiary, which provides preclinical CRO services and rents out Wilex’s antibody-drug conjugate technology.
Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:
ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.
With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.